Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Therapeutics (RAPT) over the last 7 years, with Dec 2024 value amounting to $152.9 million.

  • Therapeutics' Cash from Financing Activities rose 31147.82% to $143.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $153.3 million, marking a year-over-year increase of 10495.02%. This contributed to the annual value of $152.9 million for FY2024, which is 10463.37% up from last year.
  • According to the latest figures from FY2024, Therapeutics' Cash from Financing Activities is $152.9 million, which was up 10,463.37% from $1.4 million recorded in FY2023.
  • In the past 5 years, Therapeutics' Cash from Financing Activities registered a high of $152.9 million during FY2024, and its lowest value of $1.4 million during FY2023.
  • Over the past 3 years, Therapeutics' median Cash from Financing Activities value was $131.2 million (recorded in 2022), while the average stood at $95.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 98.90% in 2023, then surged by 10,463.37% in 2024.
  • Therapeutics' Cash from Financing Activities (Yearly) stood at $75.5 million in 2020, then skyrocketed by 87.49% to $141.5 million in 2021, then decreased by 7.28% to $131.2 million in 2022, then crashed by 98.90% to $1.4 million in 2023, then skyrocketed by 10,463.37% to $152.9 million in 2024.